Table 2 Randomized phase III trials evaluating Cetuximab in combination with chemotherapy in first line treatment of metastatic CRC
Trials in first line treatment (K-RAS wild type) | Results | ||||
|---|---|---|---|---|---|
Trial name/Author | No | Treatments | ORR (%) | PFS (months) (first end point) | OS (months) |
CRYSTAL (2009) [28] (phase 3) | 599 | FOLFIRI ± Cetiximab | 59 vs. 43 (p = 0.03) | 9.9 vs. 8.7 (HR = 0.68; 95% CI, 0.50 to 0.94) | 23.5 vs. 20 (HR = 0.80) |
OPUS (2009) [29] (phase 2) | 338 | FOLFOX ± Cetuximab | 61 vs. 37 (p = 0.01) | 8.3 vs. 7.2 (HR = 0.57; p = 0.016) | 22.8 vs. 18.5 (HR = 0.86) |